Skip to content

Company

Translational Sciences (United States)

Memphis, United States · translationalsciences.com

Manage this page

Citations, last 5 years: 26
Works, last 5 years: 38
h-index: 12
Scientists listed: 0
Grants since 2016: 11

Grants received

2021–2023 · research · R44

Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial

Sun Yong Jeong · Translational Sciences (United States) · funded by National Institutes of Health

$1.4MVenous Thromboembolism Diagnosis and Management

2021–2025 · research · R44

Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial

Sun Yong Jeong · Translational Sciences (United States) · funded by National Institutes of Health

$1.4MVenous Thromboembolism Diagnosis and Management

2019–2024 · research · R44

Preventing Neurovascular Matrix Degradation and Hemorrhage in Acute Ischemic Stroke

Sun Yong Jeong · Translational Sciences (United States) · funded by National Institutes of Health

$1.2MProtease and Inhibitor Mechanisms

2019–2025 · research · R44

Preventing Neurovascular Matrix Degradation and Hemorrhage in Acute Ischemic Stroke

Sun Yong Jeong · Translational Sciences (United States) · funded by National Institutes of Health

$1.3MProtease and Inhibitor Mechanisms

2019–2021 · research · R41

Preventing Neurovascular Matrix Degradation and Hemorrhage in Acute Ischemic Stroke

Sun Yong Jeong · Translational Sciences (United States) · funded by National Institutes of Health

$336.2k

2017–2018 · research · R43

HLS Potent, novel inhibitor of fibrinolytic hemorrhage

Guy L Reed · Translational Sciences (United States) · funded by National Institutes of Health

$351.1k

2017–2022 · research · R44

HLS Potent, novel inhibitor of fibrinolytic hemorrhage- Phase II

Sun Yong Jeong · Translational Sciences (United States) · funded by National Institutes of Health

$1.1M

2017–2021 · research · R44

HLS Potent, novel inhibitor of fibrinolytic hemorrhage- Phase II

Sun Yong Jeong · Translational Sciences (United States) · funded by National Institutes of Health

$1.3M

2017–2021 · research · R44

HLS Potent, novel inhibitor of fibrinolytic hemorrhage- Phase II

Guy L Reed · Translational Sciences (United States) · funded by National Institutes of Health

$423.2k

2011–2022 · research · R44

Commercialization Readiness Pilot for Amplifying Fibrinolysis in Ischemic Stroke

Guy L Reed · Translational Sciences (United States) · funded by National Institutes of Health

$1.6MAcute Ischemic Stroke Management

2011–2022 · research · R44

Commercialization Readiness Pilot for Amplifying Fibrinolysis in Ischemic Stroke

Guy L Reed · Translational Sciences (United States) · funded by National Institutes of Health

$1.7MAcute Ischemic Stroke Management